首页> 中文期刊>医学综述 >先兆子痫生物标志物的研究进展

先兆子痫生物标志物的研究进展

     

摘要

Preeclampsia remains a leading cause of maternal and fetal mortality ,due to ineffective treatment and diag-nostic strategies,compounded by the lack of clarity on the etiology of the disorder.Currently,combined biomarkers of pre-eclampsia include cytokines,proteins,angiogenic and antiangiogenic factors that have a fundamental role in the pathogenesis and etiology of preeclampsia.Although several clinical and biological markers of preeclampsia have been evaluated ,they have proven to be ineffective in providing a defnitive diagnosis during the various stages of the disorder.Consolidation of the current state of biomarkers in preeclampsia indicates that there is no single biomarker of the disorder that can be objectively utilized as a defnitive early biomarker of preeclampsia.However,placenta-derived exosomes,a key constituent of syncytiotro-phoblast microvesicles ,which may become the best biomarker for preeclampsia in the future.%先兆子痫因缺乏明确的疾病病因,诊断和治疗手段效果欠佳,仍是引起孕产妇和胎儿死亡的主要原因.目前先兆子痫的生物标志物包括细胞因子、蛋白、血管生成因子和抗血管生成因子,这些因子参与先兆子痫的发病机制,成为影响其致病的因素.目前已发现的评估先兆子痫有效性的生物标志物,在诊断先兆子痫的不同阶段时却是无效的.尚未发现可以早期诊断先兆子痫的单一生物标志物.然而,胎盘衍生的外泌体是合胞体滋养细胞的重要组成部分,未来可能成为先兆子痫的最佳生物标志物.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号